cas 186202-73-3|| where to buy tert-Butyl 5-benzyl-octahydropyrrolo-[3,4-c]pyrrole-2-carboxylate

Nombre del producto:tert-Butyl 5-benzyl-octahydropyrrolo-[3,4-c]pyrrole-2-carboxylate

IUPAC Name:tert-butyl 5-benzyl-octahydropyrrolo[3,4-c]pyrrole-2-carboxylate

Unidad de embalaje	Stock disponible	Precio($)
CM197623-250mg	in stock	ƤȦ
CM197623-1g	in stock	Ƌȷǆ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 186202-73-3 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :186202-73-3; Fórmula molecular:C18H26N2O2; Punto de fusión:-; Código de sonrisas:O=C(N1CC(CN(CC2=CC=CC=C2)C3)C3C1)OC(C)(C)C; Densidad:

: Número de catálogo:CM197623; Peso molecular:302.42; Punto de ebullición:; Nº Mdl:MFCD18909636; Almacenamiento:Store at 2-8°C.

: Pyrrolidines; Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

: Seltorexant; Johnson & Johnson pivotal study of Seltorexant shows statistically significant and clinically meaningful improvement in depressive symptoms and sleep disturbance outcomes. Seltorexant meets all primary and secondary endpoints in the pivotal Phase 3 MDD3001 clinical trial of adult and elderly patients with major depressive disorder (MDD) with insomnia symptoms.
Orexin signaling pathways are found to be associated with depression and anxiety. Orexin neurons receive and transmit signals throughout the central nervous system (CNS) that are modulated by their specific receptors (OX1R, OX2R). Seltorexant is an investigational first-in-class selective antagonist of ORX2 receptor. It is developed as an adjunctive therapy for MDD and for the treatment of insomnia disorder.